Mereo BioPharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Mereo BioPharma Group plc (MREO) Misses Q2 EPS by 1c
August 13, 2024 8:55 AM EDTMereo BioPharma Group plc (NASDAQ: MREO) reported Q2 EPS of ($0.02), $0.01 worse than the analyst estimate of ($0.01).
For earnings history and earnings-related data on Mereo BioPharma Group plc (MREO) click here.
... More